Last edition
News about
Aurobindo Pharma Wins UK MHRA Approval for Dazublys Trastuzumab Biosimilar
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys, used in the treatment of HER2-positive breast and gastric cancers.
Pacific Software Acquires 107 Canada from PurMinds
Pacific Software Inc. has acquired 10763942 Canada Inc. (107 Canada) and its PurMinds asset portfolio, strengthening its position in clinical-stage neuromedicine with a pipeline targeting neurological and psychiatric disorders.
Cold Chain Technologies Expands APAC Footprint with New Investments and Partnerships
Cold Chain Technologies (CCT) is strengthening its presence in the Asia Pacific (APAC) region with a series of investments and partnerships.
Cantargia Secures US Patent for Nadunolimab in Cancer Combination Therapies
Cantargia has announced that the United States Patent and Trademark Office (USPTO) has granted a new patent covering its antibody, nadunolimab.
Thermo Fisher Scientific Unveils Manufacturing Centre of Excellence Site in North Carolina, US
Thermo Fisher Scientific has inaugurated a 375,000 square feet carbon-neutral manufacturing centre of excellence in Mebane, North Carolina, designed to produce over 40 million laboratory pipette tips per week and strengthen the US life sciences supply chain.
Clyra Medical Technologies Appoints David Zansitis as Vice President of Clinical Affairs
In this new role, David Zansitis will provide strategic clinical leadership, partnering with Clyra’s Chief Medical Officer to expand the company’s clinical roadmap.
This New Sensor Can Diagnose Diabetes Within Minutes Using Breath Sample
A research team led by an associate professor at Penn State has developed a sensor that can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample.
AiMeD Urges Balanced Approach to GST Rates on Medical Devices
AiMeD noted that proposed GST changes—to either five percent or 18 percent—both present significant risks requiring nuanced consideration.
This marks the third collaboration BioArctic has entered into with partners using the BrainTransporter technology.
Dr Reddy's Welcomes Unified GST Reform to Support Pharma Manufacturing
Reddy said he expects the reform to address these critical issues, improve medicine affordability, and enhance India’s competitiveness and innovation in the global pharmaceutical supply chain. He emphasised that a reformed GST system would not only benefit patients but also reinforce India’s role in global healthcare security.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy